Depression of cardiac function by bisantrene.
Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.
D000873:Anthracenes / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy; D001933:Brain Stem; D002648:Child; D005910:Glioma / Q000188:drug therapy; D006331:Heart Diseases / Q000139:chemically induced*; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D013997:Time Factors
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene